Navigation Links
Mindray Announces Up to $100 Million Share Repurchase Program
Date:11/7/2011

SHENZHEN, China, Nov. 7, 2011 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited ("Mindray" or "Company", NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has approved a share repurchase program. The share repurchase program is authorized to be in effect through December 2012.

Under the program, Mindray is authorized to repurchase up to US$100 million worth of its issued and outstanding ordinary shares, from time to time, in open-market purchases on the NYSE Euronext of its American Depositary Shares ("ADSs") at prevailing market prices, in trades pursuant to a Rule 10b5-1 repurchase plan, or otherwise, in accordance with applicable federal securities laws, including the anti-manipulation provisions of Rule 10b-18, promulgated under the U.S. Securities Exchange Act of 1934, as amended ("Rule 10b-18"). The Company expects to use cash, internally generated funds, and/or bank borrowings to finance the repurchase.

Repurchases will be made at management's discretion, subject to restrictions on price, volume, and timing. The timing and extent of any purchases will depend upon market conditions and the trading price of its ADSs, as well as other factors. The repurchase program does not obligate Mindray to make repurchases at any specific time or situation. Mindray's Board will periodically review the share repurchase program and may authorize adjustments to the program's terms and size. The share repurchase program may also be suspended or discontinued at any time.

Mr. Xu Hang, Chairman and co-Chief Executive Officer of Mindray, commented, "This share buyback program reflects our confidence in the long-term growth prospects of Mindray, as well as our commitment to increasing shareholder value. In addition, we believe we have a strong balance sheet and expect to continue to actively pursue other growth opportunities."

About Mindray Medical International Limited

We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit: http://ir.mindray.com

Forward Looking Statements

This press release contains "forward-looking statements," including, among other things, Mindray's anticipated repurchase of its ADSs and the expected duration of the repurchase program, and the statement that Mindray may repurchase all US$100 million worth of ADSs, or no ADSs, or any amount in between, and lengthen or shorten the repurchase period, depending on the trading price of its ADSs, which may be positively or negatively impacted by the repurchase program, market conditions, determinations following the date of this announcement to use such funds for other purposes, or for other reasons; that Mindray expects to use cash, internally generated funds, and/or bank borrowings to finance the repurchase; that Mindray's Board will periodically review the share repurchase program and may authorize adjustments to the program's terms and size; that the share repurchase program may also be suspended or discontinued at any time; and that Mindray will continue to actively pursue other growth opportunities.  These forward-looking statements are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. For a discussion of important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 4 of our 2010 Annual Report filed with the Securities and Exchange Commission on April 8, 2011. We undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Such information speaks only as of the date of this release.

For investor and media inquiries please contact:

In the U.S:
Hoki Luk
Western Bridge, LLC
Tel: +1-646-808-9150
Email: hoki.luk@westernbridgegroup.com

In China:
Cathy Gao
Mindray Medical International Limited
Tel: +86-755-8188-8023
Email: cathy.gao@mindray.com


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mindray Announces Third Quarter 2011 Financial Results
2. Mindray Medical to Exhibit at MEDICA 2011 in Dusseldorf, Germany from November 16-19, 2011
3. Mindray Medical to Exhibit New Products at 66th China International Medical Equipment Fair
4. Mindray to Report Third Quarter 2011 Financial Results on November 7, 2011
5. Mindray Introduces Enhancements for M Series Ultrasound Platforms at ASA
6. Mindray Announces Expansion of its A Series Anesthesia Portfolio
7. Mindray Introduces DP-50 Portable Ultrasound System in the U.S.
8. Mindray Announces Second Quarter 2011 Financial Results
9. Mindray to Report Second Quarter 2011 Financial Results on August 8, 2011
10. Mindray Medical Provides Mid-Year Update on Product Development
11. Mindray Medical to Acquire a Controlling Stake in Suzhou Hyssen Electronics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... North Carolina , 12 februari 2016 ... Inc. (AAI/CML), een toonaangevende leverancier van productie ... en biotechnologische industrieën, kondigt vandaag een uitbreiding ... mogelijkheden op haar locatie in ... vraag heeft geleid tot meerdere recente investeringen. ...
(Date:2/11/2016)... The primary goal of this research is to analyze ... of liquid biopsy. Key information the survey seeks to ... liquid biopsy adoption amidst future users - Predominantly used ... Sample inflow to conduct liquid biopsy tests - Preference ... on. - Correlation analysis of sample type and biomarker ...
(Date:2/11/2016)... 2016  Walgreens has committed to provide drug disposal ... Washington, D.C. as part of a program ... by shareholder advocacy organization As You Sow. Conrad ... people hold on to unneeded drugs because they lack easily ... --> Conrad MacKerron , Senior Vice President ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article ... to account for a significant portion of hernia repairs throughout the United States. Commenting ... Hills Hernia Center notes that this trend has not only been expected, but it ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television ... a demanding job, and no time to decompress, Rabinowitz found herself drawn to a ... meditation for its impact on her life, implementing a 20-minute-per-day meditation practice with her ...
(Date:2/12/2016)... ... 2016 , ... Itopia, a leader in cloud services automation ... Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This integration ... and medium business (SMB) clients. , In recent years, BI and ...
(Date:2/12/2016)... ... ... The Jones Agency, a family owned insurance company with offices serving Arlington, ... drive with the Tarrant Area Food Bank in the hopes of alleviating hunger for ... the Tarrant County Food Bank offers hope and security to the one in six ...
Breaking Medicine News(10 mins):